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ABSTRACT 
The objective of the current study was the pre-clinical evaluation of alfuzosin in rabbits. A simple, specific and simple HPLC method has been developed for 
estimation of Alfuzosin with 100 µL of rabbit plasma using Doxazosin as an internal standard (IS). The Waters HPLC with PDA detector at 245 nm. A simple 
protein precipitation extraction process with acetonitrile was used to extract Alfuzosin and IS (Doxazosin) from rabbit plasma.  The total run time was 3.00 
min and the elution of Alfuzosin and Doxazosin occurred at 1.49 min and 2.14 min, this was achieved with a mobile phase consisting of  buffer : acetonitrile 
(60:40, v/v) at a flow rate of 0.80 mL/min on a Inertsil C 8 (150 x 4.6 mm, 5 µm) column. Buffer was prepared by mixing 0.02 M potassium dihydrogen 
orthophosphate and 1mL triethyl amine  in 1000 mL and it was adjusted to (pH-3.5) with ortho phosphoric acid. The developed method was validated in rabbit  
plasma with a lower limit of quantitation of 0.05 µg/mL for Alfuzosin.  A linear response function was established for the range of concentrations 0.05 to 5.0 
µg/mL (r > 0.998) for Alfuzosin. The intra and inter-day precision values for Alfuzosin met the acceptance criteria as per FDA guidelines. Alfuzosin was 
stable in a set of stability studies viz., bench-top, auto-sampler and freeze/thaw cycles. This method is free from interference from the plasma blank or solvents 
used during the optimization. The current fast track assay method was successfully applied for the oral pharmacokinetic studies of 10 mg extended release 
tablets of Alfuzosin Hydrochloride and its in vivo evaluation with reference formulations. 
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INTRODUCTION  
Alfuzosin  Hydrochloride  (Figure  1)  belongs  to  a  group  of 
medications known as alpha-1 receptor antagonists. It is used 
to treat the symptoms of enlarged prostate (benign prostatic 
hyperplasia or BPH). The prostate gland commonly becomes 
larger in older men. Prostate gland enlargement is also called 
benign prostatic hyperplasia (BPH).Alfuzosin helps to relax 
the muscles in the prostate and the opening of the bladder, 
which in turn improves urine flow and decreases symptoms 
of BPH
1. Alfuzosin does not slow or stop the progression of 
enlarged prostate. It can cause problems with passing urine, 
such as having to wait before your urine starts to flow, taking 
longer at the toilet, dribbling, and a feeling that your bladder 
is not quite empty. Alfuzosin works by relaxing the muscles 
around your bladder and prostate so that you can pass urine 
more easily
2. Alfuzosin is readily absorbed after oral doses 
and peak plasma concentration is achieved within 0.5 to 3 
hours  after  a  dose;  bioavailability  is  about  64%.  It  is 
extensively  metabolized  in  the  liver,  mainly  by  the 
cytochrome  P450  iso  enzyme  CYP3A4,  to  inactive 
metabolites that are excreted primarily in feces via the bile. 
About 11% of a dose is excreted unchanged in the urine
3. 
Alfuzosin differs from other 1-adrenergic receptor blockers 
by the absence of a piperidine moiety and the presence of a di 
amino propyl spacer, which confers Alfuzosin with specific 
biochemical properties. Affinity studies on human-cloned 1- 
receptor  subtypes  show  that  Alfuzosin,  like  terazosin  and 
Doxazosin,  is  devoid  of  significant  receptor  subtype 
selectivity
4.  Alfuzosin  undergoes  extensive  metabolism  by 
the liver, with only 11% of the administered dose excreted 
unchanged  in  the  urine.  Alfuzosin  is  metabolized  by  three 
metabolic  pathways:  oxidation,  O-demethylation,  and  N-
dealkylation.  The  metabolites  are  not  pharmacologically 
active.  CYP3A4  is  the  principal  hepatic  enzyme  isoform 
involved in its metabolism
5. The absolute bioavailability of 
Alfuzosin  hydrochloride  under  fed  conditions  is  49%. 
Following multiple dosing of 10 mg Alfuzosin hydrochloride 
under fed conditions, the time to maximum concentration is 8 
hours. Cmax and AUC0-24 are 13.6 (SD = 5.6) µg/mL and 
194  (SD  =  75)  ng•h/mL,  respectively.  Alfuzosin 
hydrochloride  exhibits  linear  kinetics  following  single  and 
multiple dosing up to 30 mg. Steady-state plasma levels are 
reached  with  the  second  dose  of  Alfuzosin  hydrochloride 
administration. Steady-state Alfuzosin plasma concentrations 
are 1.2- to 1.6-fold higher than those observed after a single 
administration
6. 
Pre  clinical  and  clinical  applications  by  HPLC  and  LC-
MS/MS  are  the  traditional  trend  to  evaluate  the 
pharmacokinetic profiles of drugs in preclinical species and 
humans
7-12. The objective of the current study was the clinical 
evaluation  of  Alfuzosin  extended  release  tablets  with  the 
reference  formulation.  There  is  significant  number  of 
analytical  methods  available  in  the  literature  for  the 
determination  of  Alfuzosin  in  plasma  and  in  various 
pharmaceutical dosage forms. The most widely used methods 
involve  high-performance  liquid  chromatography  (HPLC) 
with  fluorimetric  and  luminescence  detection,  achieving 
lower limits of quantification (LLOQ) of around 1 ng/ml
13-19. 
A  highly  sensitive  and  rapid  tandem  mass  spectrometry 
method for Alfuzosin in plasma and LC-ESI-MS/MS method 
for simultaneous quantification of Alfuzosin and solifenacin 
in  human  plasma  have  been  reported 
20-21.  The  calibration 
range for Alfuzosin was 0.391-32.3 and 0.25- 25 ng/ml. 
 
MATERIALS AND METHODS 
Chemicals and reagents 
Alfuzosin Hydrochloride (purity 99.6%) was procured from 
vivan  life  sciences  (Dr.Reddys  Labotatiers  Ltd,  India. 
Doxazocin  Mesylate(Figure  1)  (purity  98.9%)  from 
Clearsynth labs, India. All the compounds were found to be 
>98.5%  purity  determined  by  chromatographic  (HPLC) 
analysis.    HPLC  grade  of  acetonitrile;  analytical  grade 
potassium dihydrogen orthophosphate, ortho phosphoric acid, 
K2EDTA  was  purchased  from  Merck  Specialties  Pvt.  Ltd, Kishore Kumar Hotha et al. IRJP 2012, 3 (11) 
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Mumbai, India. All aqueous solutions including the buffer for 
the  mobile  phase  were  prepared  with  Milli  Q  (Millipore, 
Milford, MA, USA) grade water.   
HPLC operating conditions  
The  HPLC  system,  used  for  method  development,  and 
method validation was waters HPLC system equipped with a 
diode  array  detector,  from  Waters  Corp.  (Milford,  MA, 
USA). The output signal was monitored and processes using 
Empower software (Waters). 
Preparation of stock and standard solutions 
Primary  stock  solutions  of  Alfuzosin  Hydrochloride  for 
preparation  of  standard  and  quality  control  (QC)  samples 
were  prepared  from  separate  weighing.  The  primary  stock 
solutions were prepared in acetonitrile (1000 µg/mL).  The IS 
stock solution of 1000 µg/mL was prepared in acetonitrile. 
The stock solutions of Alfuzosin and IS were stored at 4 °C, 
which  were  found  to  be  stable  for  one  month  (data  not 
shown)  and  successively  diluted  with  acetonitrile:  water 
(50:50,  v/v)  to  prepare  working  solutions  to  prepare 
calibration  curve  (CC).  Another  set  of  working  stock 
solutions  of  Alfuzosin  were  made  in  acetonitrile  (from 
primary stock) for preparation of QC samples. Working stock 
solutions were stored approximately at 4 °C for a week (data 
not  shown).    Appropriate  dilutions  of  Alfuzosin  stock 
solution  was  made  in  acetonitrile:  water  (50:50,  v/v)  to 
produce working stock solutions. Working stocks were used 
to  prepare  plasma  calibration  standards.  A  working  IS 
solution (125 µg/mL) was prepared in methanol. Calibration 
samples were prepared by spiking 100 µL of control rabbit 
plasma with the appropriate working solution of the analyte 
(10 µL) and IS (10 µL) on the day of analysis. Samples for 
the determination of precision and accuracy were prepared by 
spiking  control  rabbit  plasma  in  bulk  with  Aluzosin  at 
appropriate concentrations [0.05 (LLOQ), 0.15 (LQC), 2.00 
(MQC) and 4.70 (HQC) µg/mL] and 50 µL plasma aliquots 
were  distributed  into  different  tubes.  All  the  samples  were 
stored at -20 ± 4 °C.  
Recovery  
The  efficiency  of  Alfuzosin  and  IS  extraction  from  rabbit 
plasma was determined by  comparing the responses of the 
analytes extracted from replicate QC samples (n = 6) with the 
response  of  analytes  from  post  extracted  plasma  standard 
sample  at  equivalent  concentrations  by  liquid/liquid 
extraction process. Recoveries of Alfuzosin was determined 
at  QC  low,  QC  medium  and  QC high  concentrations  viz., 
[0.15 (LQC), 2.50 (MQC) and 4.70 (HQC) µg/mL], whereas 
the  recovery  of  the  IS  was  determined  at  a  single 
concentration of 125 µg/mL
22.  
Sample preparation 
A  simple  protein  precipitation  method  was  followed  for 
extraction of Alfuzosin from rabbit plasma. To an aliquot of 
100 µL plasma, IS solution (10 µL of 125 µg/mL) was added 
and mixed  for  15  sec  on  a  cyclomixer  (Remi  Instruments, 
Mumbai, India). After the addition of 1 mL of acetonitrile, 
the  mixture  was  vortexed  for  5  min;  followed  by 
centrifugation  for  15  min  at  3000  rpm  on  Multifuge  3
SR 
(Heraus,  Germany).    The  supernatant  layer  (1.8  mL)  was 
separated and was injected onto HPLC system. 
 
VALIDATION PROCEDURES 
A  full  validation  according  to  the  FDA  guidelines  (US 
DHHS, FDA, CDER, 2001) was performed for the assay of 
Alfuzosin in rabbit plasma
22.
   
Specificity and selectivity 
The  specificity  of  the  method  was  evaluated  by  analyzing 
rabbit  plasma  samples  from  at  least  six  different  lots  to 
investigate the potential interferences at the LC peak region 
for analytes and IS.   
Calibration curve 
The eight point calibration curve (0.05, 0.100, 0.250, 0.500, 
2.00, 3.00, 4.00, and 5.00 µg/mL) was constructed by plotting 
the peak area ratio of each analyte: IS against the nominal 
concentration  of  calibration  standards  in  rabbit  plasma.  
Following the  evaluation  of  different  weighing  factors,  the 
results were fitted to linear regression analysis with the use of 
1/X
2  (X:  concentration)  weighting  factor.  The  calibration 
curve  had  to  have  a  correlation  coefficient  (r)  of  0.99  or 
better.  The  acceptance  criteria  for  each  back-calculated 
standard  concentration  were  ±  15%  deviation  from  the 
nominal value except at LLOQ, which was set at ± 20% 
22. 
Precision and accuracy 
The  intra-assay  precision  and  accuracy  were  estimated  by 
analyzing six replicates containing Alfuzosin at four different 
QC levels i.e., [0.05 (LLOQ), 0.15 (LQC), 2.50 (MQC) and 
4.70 (HQC) µg/mL] in plasma. The inter-assay precision was 
determined by analyzing the four levels QC samples on four 
different  runs.    The  criteria  for  acceptability  of  the  data 
included  accuracy  within  ±  15%  deviation  (SD)  from  the 
nominal  values  and  a  precision  of  within  ±  15%  relative 
standard deviation (RSD) except for LLOQ, where it should 
not exceed ± 20% of SD 
22. 
Stability experiments 
The stability of Alfuzosin and IS in the injection solvent was 
determined periodically by injecting replicate preparations of 
processed plasma samples for up to 32 h (in the auto sampler 
at  5  °C)  after  the  initial  injection.  The  peak-areas  of  the 
analyte  and  IS  obtained  at  initial  cycle  were  used  as  the 
reference  to  determine  the  stability  at  subsequent  points. 
Stability of Alfuzosin in plasma during 6 h (bench-top) was 
determined  at  ambient  temperature  (24  ±  2  °C)  at  two 
concentrations  (2.50    and  4.70  µg/mL;  in  six  replicates. 
Freezer stability of Alfuzosin rabbit plasma was assessed by 
analyzing the LQC and HQC samples stored at -20 ± 4 °C for 
at least 30 days.  The stability of alfuzosin in rabbit plasma 
following  three  freeze-thaw  cycles  was  assessed  using  QC 
samples spiked with Alfuzosin.  The samples were stored at -
20 ± 4 °C between freeze/thaw cycles.  The samples were 
thawed  by  allowing  them  to  stand  (unassisted)  at  room 
temperature for approximately 2 h.  The samples were then 
returned to the freezer.  The samples were processed using 
the same procedure as described in the sample preparation 
section. Samples were considered stable if assay values were 
within the acceptable limits of accuracy (i.e., ± 15% SD) and 
precision (i.e., ± 15% RSD)
 7-22.  
PHARMACOKINETIC STUDY 
In the present study in vivo clinical study of Alfuzosin Hcl 
extended  release  tablets  was  performed  in  healthy  rabbits 
(New  Zealand,  White)  of  either  sex  weighing  (2.8-3.2 kg) 
were  divided  into  2  groups,  each  consisting  of  6  animals. 
First  group  received  test  formulation  of  extended  release 
tablets  of  Alfuzosin  Hydrochloride  (10 mg).  Second  group 
received the Reference tablets (Uroxatral Lot .No:XG33) of 
Alfuzosin Hcl 10 mg. The tablet was put behind the tongue to 
avoid biting by rabbit. Food was withdrawn from the rabbits 
12 hr before drug administration and until 48 hr post dosing. 
All rabbits have access to water during the study period. The Kishore Kumar Hotha et al. IRJP 2012, 3 (11) 
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Institute  Animal  Ethical  Committee  approved  the  study 
protocol.  Blood samples were collected at predose, 0.30, 1.0, 
2, 4, 6, 8, 10, 12, 24, 36, and 48 hr from marginal ear vein 
into K2EDTA tubes as anticoagulant. Collected samples were 
centrifuged  at  2000-3000  rpm  for  10  minutes  (Remi 
Equipment, Mumbai, India). The plasma samples were stored 
at refrigerator condition until analysis.  
An aliquot of 100 µL of thawed plasma samples were spiked 
with IS and processed as mentioned in sample preparation 
section.  Along  with  study  samples,  QC  samples  at  low, 
medium  and  high  concentration  were  assayed  in  duplicate 
and  were  distributed  among  unknown  samples  in  the 
analytical run.  The criteria for acceptance of the analytical 
runs encompassed the following: (i) not more than 33% of 
the  QC  samples  were  greater  than  ±  15%  of  the  nominal 
concentration (ii) not less than 50% at each QC concentration 
level  must  meet  the  acceptance  criteria.  Plasma 
concentration-time data of Alfuzosin was analyzed by non-
compartmental  method  using  WinNonlin  Version  5.1 
(Pharsight Corporation, Mountain View, CA). 
 
 
Table 1: Calibration Curve Data of Alfuzosin 
STD 
Name 
Nominal Concentration 
(µg/mL) 
Peak 
Area(Mau) 
IS Area(Mau)  Drug/IS 
ratio 
Calculated Concentration 
(µg/mL) 
% Recovery 
STD-1  0.050  3502  292680  0.012  0.049  98.00 
STD-2  0.100  7170  294259  0.024  0.098  98.00 
STD-3  0.250  18020  293831  0.061  0.26  104.00 
STD-4  0.500  35600  292680  0.122  0.49  98.00 
STD-5  2.000  143402  295242  0.486  2.05  102.50 
STD-6  3.000  215000  289654  0.742  3.02  100.67 
STD-7  4.000  286854  291456  0.984  4.01  100.25 
STD-8  5.000  358585  290248  1.235  5.06  101.20 
 
Table 2: Intra and inter-day precision determination of Alfuzosin quality controls in rabbit 
  Alfuzosin 
Intraday variation (Six replicates at each concentration) 
Theoretical concentration 
(µg/mL) 
Measured concentration (µg/mL) 
Mean  SD  RSD  Accuracy (%) 
0.05  0.049  0.002  4.4  97.3 
0.15  0.149  0.007  4.5  99.3 
2.50  2.385  0.176  7.4  95.4 
4.70  4.882  0.182  3.7  103.9 
Inter day variation (Twenty four  replicates at each concentration) 
0.05  0.051  0.005  9.3  102.7 
0.15  0.155  0.010  6.3  103.1 
2.50  2.475  0.178  7.2  99.0 
4.70  4.995  0.191  3.8  106.3 
Plasma R.S.D: Relative standard deviation (S.D x 100/Mean) 
 
Table 3: Stability data of Alfuzosin quality controls in rabbit plasma 
Nominal 
conc. (µg/mL) 
 
Stability 
ASF 
Mean ± S.D
a n = 6 (µg/mL)  Accuracy (%)
b  Precision (% CV) 
 
 
 
 
0.15 
0 h (for all) 
3
rd freeze-thaw 
6 h (bench-top) 
32 h (in-injector) 
30 day at -20°C 
0.149± 0.007 
0.157 ± 0.009 
0.154 ± 0.011 
0.158 ± 0.012 
0.161 ± 0.008 
99.3 
105.4 
103.4 
106.0 
108.1 
4.5 
5.7 
7.2 
7.3 
4.8 
 
 
 
 
4.70 
0 h (for all) 
3
rd freeze-thaw 
6 h (bench-top) 
32 h (in-injector) 
30 day at -20°C 
4.882 ± 0.182 
5.150 ± 0.183 
4.940 ± 0.227 
5.007 ± 0.031 
5.272 ± 0.110 
103.9 
105.5 
101.2 
102.6 
108.0 
3.7 
3.6 
4.6 
0.6 
2.1 
 
a Back-calculated plasma concentrations;  
b(Mean assayed concentration / mean assayed concentration at 0 h) x 100 
 
Table 4: Pharmacokinetic Data of Alfuzosin Reference Formulation (Uroxatral, Lot no: XG33) 
Form  Subject  Tmax  Cmax  AUClast  AUCINF_obs  Kel  Half Life  AUC_%Extrap_obs 
Reference  1  6.00  2.08  38.59  40.76  0.06  10.77  5.34 
2  6.00  2.09  36.44  40.88  0.04  19.23  10.86 
3  6.00  2.21  37.58  38.23  0.09  7.53  1.71 
4  6.00  2.38  29.50  32.54  0.05  14.04  9.34 
5  6.00  2.26  35.84  38.00  0.05  13.60  5.68 
6  6.00  2.16  24.04  24.71  0.12  5.77  2.70 
N  6  6  6  6  6  6  6 
Mean  6.000  2.197  33.664  35.852  0.069  11.826  5.937 
SD  0.000  0.113  5.690  6.241  0.032  4.882  3.596 
Min  6.00  2.08  24.04  24.71  0.04  5.77  1.71 
Max  6.00  2.38  38.59  40.88  0.12  19.23  10.86 
CV%  0.0  5.2  16.9  17.4  45.8  41.3  60.6 
Geometric Mean  6.000  2.194  33.216  35.334  0.063  10.946  4.917 
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Table 5: Pharmacokinetic Data of Alfuzosin Test Formulation 
Form  Subject  Tmax  Cmax  AUClast  AUCINF_obs  Kel  Half Life  AUC_%Extrap_obs 
Test  1  6.00  2.10  23.78  26.27  0.04  17.26  9.48 
2  6.00  1.98  38.35  39.96  0.07  10.16  4.03 
3  8.00  2.01  35.41  39.48  0.04  17.66  10.32 
4  8.00  2.15  42.76  48.20  0.04  17.95  11.28 
5  6.00  2.32  29.12  31.79  0.05  14.26  8.41 
6  6.00  2.28  38.30  39.90  0.06  12.36  4.02 
N  6  6  6  6  6  6  6 
Mean  6.667  2.140  34.619  37.602  0.048  14.941  7.925 
SD  1.033  0.139  6.959  7.601  0.012  3.221  3.165 
Min  6.00  1.98  23.78  26.27  0.04  10.16  4.02 
Max  8.00  2.32  42.76  48.20  0.07  17.95  11.28 
CV%  15.5  6.5  20.1  20.2  24.4  21.6  39.9 
Geometric 
Mean 
6.604  2.136  33.982  36.925  0.047  14.626  7.294 
 
 
 
 
Figure 1: Structural representation of Alfuzosin and Doxazosin 
 
 
Figure 2: (a) Blank Plasma Chromatogram of Alfuzosin 
 
 
(b) LLOQ Chromatogram of Alfuzosin 
 
 
(c) In vivo sample Chromatogram of Alfuzosin 
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(d)  Aqueous Standard Chromatogram of Alfuzosin 
 
 
(e)  Calibration curve for alfuzosin 
 
Figure 3: Comparison of Individual plasma concentration profiles of 6 rabbits after the administration of 10 mg Alfuzosin Extended release tablet 
test formulation 
 
 
Figure 4: a) Pharmacokinetic profile of Test formulation 
 
 
(b)Pharmacokinetic profile of Reference formulation 
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(c) Mean Pharmacokinetic profile of Test and Reference Formulation 
 
 
RESULTS  
Liquid chromatography  
Various  mixture(s)  of  solvents  such  as  acetonitrile  and 
methanol using different buffers such as ammonium acetate, 
ammonium formate and formic acid along with altered flow-
rates  (in  the  range  of  0.1-0.5  mL/min)  were  tested  for 
complete  chromatographic  resolution  of  Alfuzosin  and  IS 
(data not shown).  The resolution of peaks was achieved with 
0.02M  potassium  dihydrogen  orthophosphate  and  1  mL 
triethyl amine in 1000 mL and acetonitrile (60:40, v/v) with a 
flow rate of 0.8 mL/min, on an Inertsil C8 (150 x 4.6 mm, 5 
µm,) and was found to be suitable for the determination of 
Alfuzosin and IS.  Chromatograms of rabbit blank, LLOQ, 
Aqueous  standard  and  rabbit  sample  chromatogram  were 
presented as Figure 2. 
Recovery 
A simple protein precipitation with acetonitrile proved to be 
robust  and  provided  cleanest  samples.  The  results  of  the 
comparison  of  neat  standards  versus  plasma-extracted 
standards  were  estimated  for  Alfuzosin  [0.15  (LQC),  2.50 
(MQC) and 4.70 (HQC) µg/mL]   the mean recovery  was 
found to be 86.75 ± 3.14, 82.15 ± 2.00 and 84.51 ± 3.66%. 
The recovery of IS at 125 µg/mL was 86.60 ± 4.42%.   
Calibration curve 
The  plasma  homogenate  calibration  curve  was  constructed 
using eight calibration standards (viz., 0.05-5.0 µg/mL). The 
calibration standard curve had a reliable reproducibility over 
the  standard  concentrations  across  the  calibration  range. 
Calibration curve was prepared by determining the best fit of 
peak-area  ratios  (peak  area  analyte/peak  area  IS)  versus 
concentration, and fitted to the y = mx + c using weighing 
factor (1/X
2).  The average regression (n = 4) was found to be 
> 0.995. The lowest concentration with the RSD < 20% was 
taken  as  LLOQ
 and  was  found  to  be  0.05  µg/mL.  The % 
accuracy  observed  for  the  mean  of  back-calculated 
concentrations for four calibration curves for Alfuzosin was 
within 98.0-102.50 respectively; while the precision (% CV) 
values  ranged  from  2.87-3.98.Experimental  data  was 
presented  in  Table  1  and  calibration  curve  represented  in 
Figure 3. 
Accuracy and precision 
Accuracy and precision data for intra- and inter-day plasma 
samples for Alfuzosin are presented in Table 2. The assay 
values  on  both  the  occasions  (intra-  and  inter-day)  were 
found to be within the accepted variable limits.  
Stability 
The predicted concentrations for Alfuzosin at 0.15 and 4.70 
µg/mL  samples  deviated  within  ±  15%  of  the  nominal 
concentrations in a battery of stability tests viz.,  in-injector 
(32 h), bench-top (6 h), repeated three freeze/thaw cycles and 
freezer stability at -20 ± 4 °C for at least for 30 days (Table 
3). The results were found to be within the assay variability 
limits  during  the  entire  process.  Experimental  data  was 
presented in Table 3. 
Pharmacokinetic study 
The present method was applied to the analysis of in vivo 
evaluation  of  test  and  reference  formulations  of  Alfuzosin 
following oral administration of 10 mg of Alfuzosin tablet. 
The sensitivity and specificity of the assay were found to be 
sufficient  for  accurately  characterizing  the  plasma 
pharmacokinetics of Alfuzosin in Rabbits. Table 4 and Table 
5  represent  the  pharmacokinetic  parameters  of  Alfuzosin 
reference and test formulations. Fig 4A and 4B represents the 
pharmacokinetic  profiles  of  test  and  reference  formulation 
and Figure 4C represents the mean pharmacokinetic profile 
of Test and reference formulation. 
 
DISCUSSION 
Validated  methods  are  essential  for  the  determination  of 
Alfuzosin concentrations in pre-clinical species plasma (for 
pre-clinical pharmacokinetics and toxic kinetic studies) and 
for clinical studies. The current validated method developed 
for Alfuzosin is very simple and sensitive and it utilizes a low 
quantity  of  aliquot  volume  (100µL)  and  short run  time  of 
3.00  min  for  each  sample  analysis.  No  interferences  from 
endogenous plasma components or other sources were found 
in  plasma  samples.  The  maximum  on-column  loading  was 
very  less  i.e.  2.5  µg/mL  for  ULOQ  (2500µg/mL),  hence 
providing  maximum  cycle  time  for  both  instrument  and 
column used for analysis. Its LLOQ can be still lowered if 
required; it offers a suitable platform for the determination of 
Alfuzosin  in  clinical  studies.    Sample  preparation  is  very 
simple and it involves Protein precipitation with acetonitrile.   
 
CONCLUSION 
In  summary,  we  have  developed  and  validated  a  simple, 
sensitive, specific and reproducible HPLC assay to quantify 
Alfuzosin  in  rabbit  plasma.  From  the  results  of  all  the 
validation parameters, the applicability of the method shall be 
extrapolated to verify the human pharmacokinetics by HPLC 
in future. 
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